levofloxacin
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia
Conditions
Pneumonia
Trial Timeline
Jan 1, 1984 → Jan 1, 1995
NCT ID
NCT00257049About levofloxacin
levofloxacin is a phase 2/3 stage product being developed by Johnson & Johnson for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00257049. Target conditions include Pneumonia.
What happened to similar drugs?
20 of 20 similar drugs in Pneumonia were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002249 | Phase 1 | Completed |
| NCT00210886 | Phase 3 | Completed |
| NCT00645437 | Phase 1 | Completed |
| NCT00236652 | Phase 3 | Completed |
| NCT00044473 | Phase 3 | Completed |
| NCT00236522 | Phase 3 | Completed |
| NCT00034736 | Phase 3 | Completed |
| NCT00236821 | Phase 3 | Completed |
| NCT00236808 | Phase 3 | Completed |
| NCT00249197 | Phase 3 | Completed |
| NCT00269932 | Phase 3 | Completed |
| NCT00249210 | Phase 3 | Completed |
| NCT00258089 | Phase 3 | Completed |
| NCT00258102 | Phase 3 | Completed |
| NCT00257062 | Phase 3 | Completed |
| NCT00257036 | Phase 2/3 | Completed |
| NCT00257049 | Phase 2/3 | Completed |
| NCT00257140 | Phase 2/3 | Completed |
Competing Products
20 competing products in Pneumonia